Trials / Completed
CompletedNCT04121286
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Allist Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312. It is anticipated that approximately 24 subjects will be enrolled in the dose-escalation phase of the study. JAB-3312 will be administered orally once daily (QD) in 21-day treatment cycles.
Conditions
- Non-small Cell Lung Cancer
- Colorectal Cancer
- Pancreatic Ductal Carcinoma
- Esophageal Squamous Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Breast Cancer
- Other Solid Tumors
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JAB-3312 | JAB-3312 will be supplied as 0.25 mg, 1.0 mg and 4.0 mg capsules. |
Timeline
- Start date
- 2020-07-14
- Primary completion
- 2022-06-17
- Completion
- 2022-06-17
- First posted
- 2019-10-09
- Last updated
- 2025-05-20
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04121286. Inclusion in this directory is not an endorsement.